Trexquant Investment LP raised its holdings in Inogen, Inc. (NASDAQ:INGN - Free Report) by 137.3% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 125,930 shares of the medical technology company's stock after acquiring an additional 72,871 shares during the quarter. Trexquant Investment LP owned approximately 0.53% of Inogen worth $1,155,000 as of its most recent SEC filing.
Several other large investors have also bought and sold shares of the stock. Meeder Asset Management Inc. acquired a new position in shares of Inogen in the 4th quarter worth approximately $56,000. Arrowstreet Capital Limited Partnership raised its holdings in shares of Inogen by 154.8% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 263,561 shares of the medical technology company's stock worth $2,417,000 after acquiring an additional 160,106 shares during the last quarter. Prudential Financial Inc. raised its position in Inogen by 141.5% in the 4th quarter. Prudential Financial Inc. now owns 360,002 shares of the medical technology company's stock valued at $3,301,000 after buying an additional 210,961 shares during the last quarter. Sei Investments Co. bought a new position in shares of Inogen during the fourth quarter valued at about $153,000. Finally, American Century Companies Inc. lifted its holdings in Inogen by 10.2% during the fourth quarter. American Century Companies Inc. now owns 54,856 shares of the medical technology company's stock worth $503,000 after acquiring an additional 5,089 shares during the period. 89.94% of the stock is owned by institutional investors.
Inogen Stock Down 3.3 %
Shares of NASDAQ:INGN traded down $0.24 during midday trading on Wednesday, hitting $6.96. 35,730 shares of the stock traded hands, compared to its average volume of 239,803. The stock has a market capitalization of $187.13 million, a PE ratio of -3.09 and a beta of 1.48. The business's 50 day moving average is $8.17 and its two-hundred day moving average is $9.19. Inogen, Inc. has a one year low of $6.40 and a one year high of $13.33.
Analyst Upgrades and Downgrades
INGN has been the topic of a number of recent research reports. Needham & Company LLC reaffirmed a "hold" rating on shares of Inogen in a research report on Wednesday, April 9th. StockNews.com lowered shares of Inogen from a "buy" rating to a "hold" rating in a report on Wednesday, February 26th.
Check Out Our Latest Research Report on INGN
About Inogen
(
Free Report)
Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Further Reading
Before you consider Inogen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inogen wasn't on the list.
While Inogen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
